Comment on: Bisphosphonates and osteonecrosis of the jaw.
Bianchi
M L
ML
Limonta
C
C
Frasunkiewicz
J
J
Biggioggero
M
M
Vai
S
S
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D019386:Alendronate / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007571:Jaw Diseases / Q000139:chemically induced* / Q000503:physiopathology; D008297:Male; D010020:Osteonecrosis / Q000139:chemically induced* / Q000503:physiopathology; D000077268:Pamidronate; D011446:Prospective Studies; D018570:Risk Assessment
D004164:Diphosphonates; D000077268:Pamidronate; D019386:Alendronate